Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G., … Ross, J. S. (2013). Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. In MODERN PATHOLOGY (Vol. 26, pp. 397A-397A). Baltimore, MD: NATURE PUBLISHING GROUP.

Al-Rohil, R., J. V. Rand, D. M. Jones, H. J. Lee, C. E. Sheehan, G. Otto, G. Palmer, et al. “Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies.” In MODERN PATHOLOGY, 26:397A-397A. NATURE PUBLISHING GROUP, 2013.

Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto G, et al. Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. In: MODERN PATHOLOGY. NATURE PUBLISHING GROUP; 2013. p. 397A-397A.

Al-Rohil, R., et al. “Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies.” MODERN PATHOLOGY, vol. 26, NATURE PUBLISHING GROUP, 2013, pp. 397A-397A.

Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto G, Palmer G, Yelensky R, Lipson D, White E, Balasubramanian S, Garcia L, Mahoney K, Richards T, Terzic S, Banning V, Curran J, Downing S, Miller V, Stephens P, Ross JS. Evaluation of Cholangiocarcinomas (CCA) by Next Generation Sequencing (NGS) Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies. MODERN PATHOLOGY. NATURE PUBLISHING GROUP; 2013. p. 397A-397A.